PHOTOCREO Michal Bednarek / Shutterstock.com
With evidence of antimicrobial resistance increasing, can innovation incentives drive pharma to fight back? Donald McNab and Mark Schuster of Marks & Clerk explore.
At the time of writing, the nations of the UK are in the process of abandoning or at least easing, the legal restrictions introduced during the COVID-19 pandemic. So, it appears that this crisis is reaching—if not an end—the end of the beginning. For the past two years, the pandemic has dominated the public scientific conversation, with enormous amounts of public and private resources being directed to its resolution.
But has the COVID-19 emergency distracted us from a well-established, but no less serious, medical threat? Described variously as “an overlooked pandemic” (E Pelfrene, R Botgros and M Cavaleri, Antimicrobial Resistance & Infection Control, 2021) and a “forgotten plight” (R Laxminarayan, The Lancet, 2022), is it now time to turn more attention and resource to the rise of antimicrobial resistance (AMR)?
Antimicrobials, such as antibiotics, are used to treat infections by disease-causing microorganisms. AMR describes the ability of microorganisms to withstand exposure to such antimicrobials, making treatments less effective or, at worst, ineffective.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
COVID-19, antimicrobial, Marks & Clerk, pandemic, innovation, R&D, patent rights, monopoly, inventions, IP policy